tiprankstipranks
Celldex Therapeutics (CLDX)
NASDAQ:CLDX
US Market
CLDX
Celldex
RESEARCH TOOLSreports
Want to see CLDX full AI Analyst Report?

Celldex (CLDX) Stock Forecast & Price Target

1,274 Followers
See the Price Targets and Ratings of:

CLDX Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Celldex
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CLDX Stock 12 Month Forecast

Average Price Target

$58.79
▲(66.63% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is $58.79 with a high forecast of $100.00 and a low forecast of $38.00. The average price target represents a 66.63% change from the last price of $35.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","41":"$41","61":"$61","81":"$81","101":"$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.785714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41,61,81,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.06,42.824615384615385,47.58923076923077,52.353846153846156,57.11846153846154,61.88307692307692,66.64769230769231,71.41230769230769,76.17692307692307,80.94153846153846,85.70615384615384,90.47076923076924,95.23538461538462,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.06,39.65428571428571,41.24857142857143,42.84285714285714,44.43714285714286,46.03142857142857,47.62571428571429,49.22,50.81428571428572,52.40857142857143,54.002857142857145,55.597142857142856,57.191428571428574,{"y":58.785714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.06,38.05538461538462,38.050769230769234,38.04615384615385,38.041538461538465,38.03692307692308,38.0323076923077,38.027692307692305,38.02307692307692,38.01846153846154,38.01384615384615,38.00923076923077,38.004615384615384,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.31,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.14,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$58.79Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CLDX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$68
Buy
92.74%
Upside
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
LifeSci Capital Analyst forecast on CLDX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
58.73%
Upside
Reiterated
08/07/26
Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
Barclays Analyst forecast on CLDX
Etzer Darout
Barclays
Barclays
$48→$53
Buy
50.23%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Celldex (CLDX)
H.C. Wainwright Analyst forecast on CLDX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$42
Buy
19.05%
Upside
Reiterated
08/07/26
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
Morgan Stanley Analyst forecast on CLDX
Judah Frommer
Morgan Stanley
Morgan Stanley
$40→$46
Buy
30.39%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on Celldex (CLDX)
Goldman Sachs Analyst forecast on CLDX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$34→$38
Hold
7.71%
Upside
Reiterated
08/07/26
Goldman Sachs Reaffirms Their Hold Rating on Celldex (CLDX)
Guggenheim Analyst forecast on CLDX
Yatin Suneja
Guggenheim
Guggenheim
$100
Buy
183.45%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (NASDAQ: XFOR), Celldex (NASDAQ: CLDX) and Climb Bio (NASDAQ: CLYM)
Canaccord Genuity Analyst forecast on CLDX
Edward Nash
Canaccord Genuity
Canaccord Genuity
$60
Buy
70.07%
Upside
Reiterated
08/06/26
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
Wells Fargo Analyst forecast on CLDX
Derek Archila
Wells Fargo
Wells Fargo
$7→$72
Buy
104.08%
Upside
Reiterated
08/06/26
Wells Fargo Reaffirms Their Buy Rating on Celldex (CLDX)
Cantor Fitzgerald Analyst forecast on CLDX
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$61
Buy
72.90%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS) and Celldex (NASDAQ: CLDX)
Leerink Partners Analyst forecast on CLDX
Thomas Smith
Leerink Partners
Leerink Partners
$78→$70
Buy
98.41%
Upside
Reiterated
07/22/26
Celldex price target lowered to $70 from $78 at LeerinkCelldex price target lowered to $70 from $78 at Leerink
Stifel Nicolaus Analyst forecast on CLDX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$68
Buy
92.74%
Upside
Reiterated
07/22/26
Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Celldex (NASDAQ: CLDX) and MaxCyte (NASDAQ: MXCT)
UBS Analyst forecast on CLDX
David Dai
UBS
UBS
$45
Buy
27.55%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on CLDX
Andy Chen
Wolfe Research
Wolfe Research
$51→$44
Buy
24.72%
Upside
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on CLDX
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CLDX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$68
Buy
92.74%
Upside
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
LifeSci Capital Analyst forecast on CLDX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
58.73%
Upside
Reiterated
08/07/26
Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target
Barclays Analyst forecast on CLDX
Etzer Darout
Barclays
Barclays
$48→$53
Buy
50.23%
Upside
Reiterated
08/07/26
Barclays Reaffirms Their Buy Rating on Celldex (CLDX)
H.C. Wainwright Analyst forecast on CLDX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$42
Buy
19.05%
Upside
Reiterated
08/07/26
Celldex: Barzo Franchise Momentum and Upcoming Catalysts Support Buy Rating with Unchanged $42 Price Target
Morgan Stanley Analyst forecast on CLDX
Judah Frommer
Morgan Stanley
Morgan Stanley
$40→$46
Buy
30.39%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on Celldex (CLDX)
Goldman Sachs Analyst forecast on CLDX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$34→$38
Hold
7.71%
Upside
Reiterated
08/07/26
Goldman Sachs Reaffirms Their Hold Rating on Celldex (CLDX)
Guggenheim Analyst forecast on CLDX
Yatin Suneja
Guggenheim
Guggenheim
$100
Buy
183.45%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (NASDAQ: XFOR), Celldex (NASDAQ: CLDX) and Climb Bio (NASDAQ: CLYM)
Canaccord Genuity Analyst forecast on CLDX
Edward Nash
Canaccord Genuity
Canaccord Genuity
$60
Buy
70.07%
Upside
Reiterated
08/06/26
Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target
Wells Fargo Analyst forecast on CLDX
Derek Archila
Wells Fargo
Wells Fargo
$7→$72
Buy
104.08%
Upside
Reiterated
08/06/26
Wells Fargo Reaffirms Their Buy Rating on Celldex (CLDX)
Cantor Fitzgerald Analyst forecast on CLDX
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$61
Buy
72.90%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS) and Celldex (NASDAQ: CLDX)
Leerink Partners Analyst forecast on CLDX
Thomas Smith
Leerink Partners
Leerink Partners
$78→$70
Buy
98.41%
Upside
Reiterated
07/22/26
Celldex price target lowered to $70 from $78 at LeerinkCelldex price target lowered to $70 from $78 at Leerink
Stifel Nicolaus Analyst forecast on CLDX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$68
Buy
92.74%
Upside
Reiterated
07/22/26
Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Celldex (NASDAQ: CLDX) and MaxCyte (NASDAQ: MXCT)
UBS Analyst forecast on CLDX
David Dai
UBS
UBS
$45
Buy
27.55%
Upside
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on CLDX
Andy Chen
Wolfe Research
Wolfe Research
$51→$44
Buy
24.72%
Upside
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on CLDX
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

3 Months
Derek ArchilaWells Fargo
Success Rate
9/12 ratings generated profit
75%
Average Return
+4.67%
Copying Derek Archila's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +4.67% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
14/15 ratings generated profit
93%
Average Return
+45.30%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +45.30% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
15/15 ratings generated profit
100%
Average Return
+64.16%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +64.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLDX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
5
6
14
14
Buy
6
6
9
11
14
Hold
1
2
1
2
2
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
16
27
30
In the current month, CLDX has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CLDX average Analyst price target in the past 3 months is 58.79.
Each month's total comprises the sum of three months' worth of ratings.

CLDX Financial Forecast

CLDX Earnings Forecast

Next quarter’s earnings estimate for CLDX is -$1.02 with a range of -$1.09 to -$0.94. The previous quarter’s EPS was -$0.94. CLDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CLDX is -$1.02 with a range of -$1.09 to -$0.94. The previous quarter’s EPS was -$0.94. CLDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.

CLDX Sales Forecast

Next quarter’s sales forecast for CLDX is $726.00K with a range of $0.00 to $3.00M. The previous quarter’s sales results were $22.00K. CLDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.
Next quarter’s sales forecast for CLDX is $726.00K with a range of $0.00 to $3.00M. The previous quarter’s sales results were $22.00K. CLDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year CLDX has Performed in-line its overall industry.

CLDX Stock Forecast FAQ

What is CLDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics’s 12-month average price target is 58.79.
    What is CLDX’s upside potential, based on the analysts’ average price target?
    Celldex Therapeutics has 66.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CLDX a Buy, Sell or Hold?
          Celldex Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Celldex Therapeutics’s price target?
            The average price target for Celldex Therapeutics is 58.79. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $38.00. The average price target represents 66.63% Increase from the current price of $35.28.
              What do analysts say about Celldex Therapeutics?
              Celldex Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of CLDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.